These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23773864)

  • 41. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
    Bailey MD; Bordeleau J; Garneau M; Leblanc M; Lemke CT; O'Meara J; White PW; Llinàs-Brunet M
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4447-52. PubMed ID: 23773863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
    Ontoria JM; Di Marco S; Conte I; Di Francesco ME; Gardelli C; Koch U; Matassa VG; Poma M; Steinkühler C; Volpari C; Harper S
    J Med Chem; 2004 Dec; 47(26):6443-6. PubMed ID: 15588076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
    Malcolm BA; Liu R; Lahser F; Agrawal S; Belanger B; Butkiewicz N; Chase R; Gheyas F; Hart A; Hesk D; Ingravallo P; Jiang C; Kong R; Lu J; Pichardo J; Prongay A; Skelton A; Tong X; Venkatraman S; Xia E; Girijavallabhan V; Njoroge FG
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1013-20. PubMed ID: 16495264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
    Ortqvist P; Vema A; Ehrenberg AE; Dahl G; Rönn R; Akerblom E; Karlén A; Danielson UH; Sandström A
    Antivir Ther; 2010; 15(6):841-52. PubMed ID: 20834096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
    J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
    Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
    Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
    J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S; Njoroge FG
    Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
    Bowsher M; Hiebert S; Li R; Wang AX; Friborg J; Yu F; Hernandez D; Wang YK; Klei H; Rajamani R; Mosure K; Knipe JO; Meanwell NA; McPhee F; Scola PM
    Bioorg Med Chem Lett; 2018 Jan; 28(1):43-48. PubMed ID: 29162454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
    Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
    J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
    Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.
    Goudreau N; Cameron DR; Bonneau P; Gorys V; Plouffe C; Poirier M; Lamarre D; Llinas-Brunet M
    J Med Chem; 2004 Jan; 47(1):123-32. PubMed ID: 14695826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
    Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.
    Colarusso S; Koch U; Gerlach B; Steinkühler C; De Francesco R; Altamura S; Matassa VG; Narjes F
    J Med Chem; 2003 Jan; 46(3):345-8. PubMed ID: 12540231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.